Participated · Equity · May 2022

Feel Therapeutics builds a platform of wearable devices, mobile apps, and clinician dashboards to collect physiological, digital, and clinical data aimed at making mental-health care more science-forward. The company shared the pitch deck it used to raise a $3.5 million round. The deck highlights traction including roughly 2,700 patients across nine countries, white papers/publications, and patents. The Ask and Use of Funds slide in the deck unusually includes investment terms and indicates a lead investor is already in place as the company seeks to round out the raise. TechCrunch cites PitchBook data suggesting the company has raised many prior financings (about eight rounds) but has not yet achieved what the article terms "proper growth." The article also notes missing elements investors would expect—competitive landscape, a coherent go-to-market or operating plan, unit economics, and SMART milestones for the use of funds—which are likely to be areas for diligence. Feel Therapeutics develops digital precision-medicine tools that provide objective and passive monitoring for mental and behavioral health, including Emotion Detection Technology covered by a recently added US patent. The company partners with pharmaceutical companies and CROs to generate clinical and real-world evidence and to bring precision Drug+ and DTx solutions to market as standalone products or alongside medications. Feel has published five studies in peer-reviewed journals and says it is expanding its evidence-generation activities. The company announced new funding from Satori Neuro, Metavallon VC, and existing backers such as SOSV and SeedtoB to support its expansion and product efforts. Leadership and governance additions — Michel Vounatsos as chairman of the advisory board and Amy Kruse of Satori Neuro as a board observer — accompany the investment. Feel is headquartered in San Francisco with additional offices in Europe and is actively recruiting in Athens and San Francisco. Feel Therapeutics develops digital biomarkers and digital therapeutics for mental health, combining the Feel Emotion Sensor wristband, a connected mobile app that provides real-time insights and advice, and a tailored telemedicine program called Feel Provider. The company targets healthcare and insurance providers, employers, and individual users to expand access to psychotherapy and reduce mental health costs. It has worked with large insurers such as SCOR and Gothaer and partners with US pharmaceutical companies to bring digital therapeutics to market. The startup employs 30 people, 25 of whom are based in Greece, and was founded by George Eleftheriou and Dr. Haris Tsirmpas. With a mission to bring objective measurement to mental health, Feel Therapeutics is pursuing FDA approval for a data-driven digital therapeutics solution for depression and anxiety and is focusing near-term on partnerships with global pharma. The company’s total funding has increased to over $10M following the latest financing.

Led · Series A · Mar 2017

Investfit is an Australia-based financial planning and advisory app that uses sophisticated predictive analytics to simulate individuals' financial futures and optimize retirement outcomes. Its technology crunches billions of calculations in real time and can simulate thousands of different investment strategies to identify the ones that maximise a client's goals. The platform is designed for advisers, planners and fund members to eliminate guesswork and reduce para-planning time. After a one-year pilot of a corporate version with AMP, founders Ed de Salis, James Claridge and Gavin Daw realised the technology could be applied directly to benefit individuals. The company recently raised $1.5M in a Series A led by Sapien Ventures. Investfit aims to expand access to powerful computing previously unavailable to advisers, with potential to improve pre- and post-retirement planning outcomes.